La plateforme OSKAR Bordeaux évolue pour rejoindre l'archive ouverte HAL. Retrouvez tous vos dépôts sur le nouveau portail HAL UB : https://u-bordeaux.hal.science/. Pour toute aide ou information, contactez-nous info@oskar-bordeaux.fr
Navigation Neurocentre Magendie - U1215 par Auteur "WIERTLEWSKI, Sandrine"
Voici les éléments 1-8 de 8
-
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 3, 2023-02-21)Article de revueLibre accès
-
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
(Multiple Sclerosis Journal. vol. 29, n° 2, pp. 236-247, 2023-02-01)Article de revue -
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
(JAMA neurology. vol. 81, n° 3, pp. 273-282, 2024-03-01)Article de revueLibre accès
-
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
(Neurotherapeutics. vol. 19, n° 2, pp. 476-490, 2022-03)Article de revueLibre accès
-
A peripheral cytotoxic nk-like cd eight t-cell subset predicts at onset an aggressive course of multiple sclerosis
Communication dans un congrès -
Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort
(Brain and Behavior. vol. 14, n° 9, pp. 3443, 2024-09)Article de revueLibre accès
-
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis
(JAMA neurology. vol. 81, n° 8, pp. 814-823, 2024-08)Article de revue -
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification among Natalizumab Users in France
(JAMA Neurology. vol. 77, n° 1, pp. 94-102, 2020-01-01)Article de revueLibre accès